GIP and obesity disorder: A recent network meta-analysis including 27 RCTs and 15,584 participants evaluated efficacy and safety of seven GLP-1 RAs and polyagonists (GLP-1/GIP or GLP-1/GIP/Glucagon) for weight management in individuals with overweight or obesity.